David Ward

Title: David Ward: Innovator in Cancer Treatment

Introduction

David Ward is a notable inventor based in Taipa, Macau. He has made significant contributions to the field of medical science, particularly in the treatment of RAS-positive diseases. His innovative approach focuses on enhancing the effectiveness of existing treatments for cancer.

Latest Patents

David Ward holds a patent for a groundbreaking invention titled "Combination treatment of RAS-positive diseases with PDE-δ inhibitor and direct autophagy inhibitor." This patent presents methods for treating RAS-positive diseases, specifically KRAS-positive non-small cell lung cancer. The invention combines a PDE-δ inhibitor, preferably deltarasin, with a direct autophagy inhibitor, such as 3-methyladenine. This combination aims to increase the apoptotic activity of the PDE-δ inhibitor by simultaneously blocking its tumor-protective autophagy. The patent also includes a kit and a pharmaceutical composition that incorporates both inhibitors, providing a new treatment option for patients suffering from RAS-positive diseases.

Career Highlights

David Ward is affiliated with the Macau University of Science and Technology, where he continues to advance his research and innovations. His work has garnered attention for its potential to improve treatment outcomes for patients with specific types of cancer.

Collaborations

David collaborates with esteemed colleagues, including Elaine Lai-Han Leung and Liang Liu. Their combined expertise contributes to the ongoing research and development of effective cancer treatments.

Conclusion

David Ward's innovative work in the field of cancer treatment exemplifies the impact of combining existing therapies to enhance patient outcomes. His contributions are paving the way for new treatment options for RAS-positive diseases, showcasing the importance of innovation in medical science.